M.D. Anderson Cancer Center
The goal of this clinical research study is to find a safe and tolerable dose of navlimetostat in combination with pumitamig that can be given to patients with MTAP-deficient advanced non-small cell lung cancer (NSCLC). The effectiveness of the study drugs will also be studied.
Primary Objectives: Phase I: To evaluate the safety of navlimetostat in combination with pumitamig. Phase II: To evaluate the efficacy of navlimetostat in combination with pumitamig. Secondary Objectives: * To evaluate toxicity and tolerability of navlimetostat in combination with pumitamig. * To evaluate efficacy outcomes including disease control rate, progression-free survival, overall survival, and duration of response. * To compare the efficacy of the combination in patients with prior ICI exposure and those without (treated with targeted therapy and/or chemotherapy). Exploratory Obje…
Inclusion Criteria: General inclusion criteria * Age ≥18 years. Because no dosing or adverse event data are currently available on the use of navlimetostat in combination with pumitamig in patients \<18 years of age, children are excluded from this study. * Have at least one measurable lesion as the target lesion based on RECIST v1.1. Lesions treated with prior local treatment (radiation, ablation, etc) are generally not considered target lesions. If the lesion with prior local treatment is the only target lesion, evidence must be provided to demonstrate disease progression. * MTAP loss as d…
Given orally once daily
Given by infusion
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.